자궁내막암 치료 시장, 기회, 성장 촉진요인, 산업 동향 분석 및 예측(2024-2032년)

The Global Endometrial Cancer Treatment Market was valued at USD 28.9 billion in 2023 and is projected to grow at a CAGR of 5.3% during 2024-2032. This growth is largely attributed to the rising global prevalence of endometrial cancer, especially among postmenopausal women. For instance, GLOBOCAN estimates indicate that in 2022, there were around 420,368 new global diagnoses of endometrial cancer (commonly referred to as uterine cancer). This statistic ranks endometrial cancer as the 15th most prevalent cancer worldwide, with an age-standardized rate (ASR) of 8.4 per 100,000 women.

As the incidence of this cancer continues to rise, especially among aging populations and those with risk factors like obesity and hormonal imbalances, the demand for effective treatment options has surged. This increase in cases has heightened the need for diagnostic tools, innovative therapies, and personalized treatment approaches, driving market growth. Furthermore, advancements in early detection and heightened awareness of endometrial cancer have played a role in the market's expansion, as a larger number of patients are now diagnosed at treatable stages, necessitating prompt and ongoing medical interventions.

The global endometrial cancer treatment industry is classified based on cancer type, treatment, stage and region.

The endometrial carcinoma segment held 62.5% market share in 2023. This dominance is largely due to the high prevalence of endometrial carcinoma, especially the endometrioid adenocarcinoma variant, which is the most frequently diagnosed type. The significant incidence of this type drives a robust demand for various treatment modalities, including surgical interventions, radiation, chemotherapy, and targeted therapies. Given its prevalence, there's a concentrated research and development effort aimed at understanding and treating endometrial carcinoma. This commitment has spurred the creation of advanced therapies and attracted increased market investments, bolstering the segment's growth.

The stage I segment generated USD 8.8 billion in 2023, as endometrial cancer is frequently detected at stage I, due to routine screenings and heightened awareness. This early detection facilitates successful surgical interventions, like hysterectomies. The favorable prognosis and elevated survival rates linked with stage I cancer treatments, which tend to be less invasive and more cost-effective, account for the segment's substantial market share. Furthermore, bolstered by improved healthcare awareness, robust screening initiatives, and extensive insurance coverage, the market value for stage I treatments sees significant support.

North America Endometrial Cancer Treatment Market was valued at USD 11.7 billion in 2023, with forecasts suggesting an increase to USD 18.1 billion by 2032. North America's market leadership is underpinned by its sophisticated healthcare infrastructure, a notably high prevalence of endometrial cancer, and considerable investments in R&D for pioneering treatments. The region's dominance is amplified by the presence of leading pharmaceutical firms and access to state-of-the-art therapies, including targeted treatments and immunotherapies. Additionally, a heightened emphasis on early detection and rising healthcare expenditures further boosts the demand for endometrial cancer treatments in North America.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of endometrial cancer
    • 3.2.1.2 Advancements in diagnostic techniques
    • 3.2.1.3 Growing awareness and focus on women's health
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of treatment
    • 3.2.2.2 Side effects associated with the treatment
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Cancer Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Endometrial carcinoma
• 5.3 Uterine sarcoma

Chapter 6 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Surgery
• 6.3 Chemotherapy
• 6.4 Radiation therapy
• 6.5 Hormone therapy
• 6.6 Targeted therapy
• 6.7 Immunotherapy

Chapter 7 Market Estimates and Forecast, By Stage, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Stage I
• 7.3 Stage II
• 7.4 Stage III
• 7.5 Stage IV

Chapter 8 Market Estimates and Forecast, By Treatment Provider, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Cancer centers
• 8.4 Ambulatory surgical centers

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Medication manufacturers
  • 10.1.1 Alpine Life Sciences Private Limited
  • 10.1.2 AstraZeneca PLC
  • 10.1.3 Eisai Co., Ltd.
  • 10.1.4 GSK plc
  • 10.1.5 Merck and Co., Inc.
  • 10.1.6 Novartis AG
  • 10.1.7 Pfizer Inc.
  • 10.1.8 Varian Medical Systems, Inc. (Siemens Healthineers AG)
  • 10.1.9 Sun Pharmaceutical Industries Limited
  • 10.1.10 Teva Pharmaceutical Industries Ltd.
• 10.2 Service providers
  • 10.2.1 Brigham and Women's Hospital
  • 10.2.2 Mayo Foundation for Medical Education and Research (MFMER)
  • 10.2.3 The University of Texas MD Anderson Cancer Center
  • 10.2.4 Institut Gustave Roussy
  • 10.2.5 National Cancer Center Research Institute